Post-Ebola virus syndrome

Last updated
Post-Ebola virus syndrome
Other namesPost Ebola syndrome
Ebola Virus Particles (7).jpg
Ebola virus particles (blue) attacking a cell (yellow)
Specialty Infectious disease
Symptoms Chest pain, fatigue, hearing loss [1]
CausesEVD
Diagnostic method Neurological observation [2]

Post-Ebola virus syndrome (or post-Ebola syndrome) is a post-viral syndrome affecting those who have recovered from infection with Ebola. [3] Symptoms include joint and muscle pain, eye problems, including blindness, various neurological problems, and other ailments, sometimes so severe that the person is unable to work. [4] Although similar symptoms had been reported following previous outbreaks in the last 20 years, health professionals began using the term in 2014 when referring to a constellation of symptoms seen in people who had recovered from an acute attack of Ebola disease. [5]

Contents

Signs and symptoms

Researchers have been aware of a group of symptoms that frequently followed Ebola virus disease for 20 years, but it became more widely reported with the large number of survivors of the deadly epidemic in West Africa in 2014. [3] [6] [7] [8] [2] Post Ebola syndrome may manifest as joint pain, muscle pain, chest pain, fatigue, hearing loss, hair loss, cessation of menstruation, and poor long-term health. Some survivors report neurological issues including memory problems and anxiety attacks. Vision loss is also frequently reported, along with eye pain, inflammation, and blurred vision. [1] Two papers published in the New England Journal of Medicine in 2015 report that symptoms include lethargy, joint pains, hair loss, and vision loss, frequently to the point of near blindness, and uveitis. [9] [10]

Mechanism

Doctors put on protective gear before entering an Ebola treatment ward in Liberia, August 2014. Preparing to enter Ebola treatment unit (2).jpg
Doctors put on protective gear before entering an Ebola treatment ward in Liberia, August 2014.

Although, there is some progress that may potentially help Ebola survivors, adequate funding and further research is required to help provide more answers about post-Ebola syndrome. [11]

Studies from previous outbreaks reveal that the virus is able to survive for months after recovery in some parts of the body such as the eyes and testes, where the immune system cannot reach. It is not known if the neurologic symptoms seen in survivors are a direct result of the virus or, instead, triggered by the immune system's response to the infection. It is known that Ebola can trigger a massive cytokine storm that can cause bleeding throughout the body, including the brain, which may explain various neurological symptoms that have been reported. [12]

Diagnosis

In terms of diagnosis, the individual may show sensitivity to light or eye redness when ocular problems are suspected. Neurologically the individual's coordination, gait and frontal release signs should be observed. [2]

Management

Management depends on the symptoms displayed, for example, if the individual indicates muscular-skeletal pain then paracetamol may be administered. If the individual presents with ocular problems, then prednisone and cyclopentolate may be used for treatment, according to the WHO. [2]

Prognosis

Viral persistence and transmission

According to a review by Brainard, et al., Ebola virus was identified in almost 3 out of 4 seminal fluid samples (18 survivors) almost 4 months after initial infection, with the last positive samples being more than 6 months (203 days) after infection had occurred. [13] Another aspect of survivors of the Ebola virus, is that it could become sexually transmitted, as the virus is present in semen nine months after the individuals are declared free of Ebola. [14] A 2017 study found the virus in the semen of some men after more than two years following the recovery from the acute infection [15] and in one case, Ebola viral RNA was identified up to 40 months after illness. [16]

At the start of 2021 an outbreak of EVD that caused 18 cases and 9 deaths in Guinea is thought to be due to a West Africa Ebola outbreak survivor. This individual apparently infected a woman more than 5 years after he himself had incurred the infection [17]

Research

An observational study, done roughly 29 months after the 2007 Bundibugyo outbreak in Uganda, found that long-term sequelae (i.e. consequences) persisted among survivors. Symptoms included eye pain, blurred vision, hearing loss, difficulty swallowing, difficulty sleeping, arthralgias, memory loss or confusion, and "various constitutional symptoms controlling for age and sex". [18]

From August through December 2014, a total of 10 patients with Ebola were treated in US hospitals; of these patients, 8 survived. In March 2015, the CDC interviewed the survivors; they all reported having had at least one adverse symptom during their recovery period. The symptoms ranged from mild (e.g. hair loss) to more severe complications requiring re-hospitalisation or treatment. The most frequently reported symptoms were lethargy or fatigue, joint pain, and hair loss. Sixty-three per cent reported having eye problems including two who were diagnosed with uveitis, 75% reported psychological or cognitive symptoms, and 38% reported neural difficulties. Although most symptoms resolved or improved over time, only one survivor reported complete resolution of all symptoms. [19]

A study published in May 2015 discussed the case of Ian Crozier, a Zimbabwe-born physician and American citizen who became infected with Ebola while he was working at an Ebola treatment centre in Sierra Leone. He was transported to the US and successfully treated at Emory University Hospital. However, after discharge Crozier began to experience symptoms including low back pain, bilateral enthesitis of the Achilles tendon, paresthesias involving his lower legs, and eye pain, which was diagnosed as uveitis. His eye condition worsened and a specimen of aqueous humor obtained from his eye tested positive for Ebola. The authors of the study concluded that "further studies to investigate the mechanisms responsible for the ocular persistence of Ebola and the possible presence of the virus in other immune-privileged sites (e.g., in the central nervous system, gonads, and articular cartilage) are warranted." The authors also noted that 40% of participants in a survey of 85 Ebola survivors in Sierra Leone reported having "eye problems", though the incidence of actual uveitis was unknown. [20]

Another study, which was released in August 2015 looked at the health difficulties reported by survivors. Calling the set of symptoms "post-Ebolavirus disease syndrome", the research found symptoms that included "chronic joint and muscle pain, fatigue, anorexia, hearing loss, blurred vision, headache, sleep disturbances, low mood and short-term memory problems", and suggested the "implementation of specialised health services to treat and follow-up survivors". [21]

Researchers from the National Institute of Neurological Disorders and Stroke (NINDS) and Liberian research partners are doing a 5-year follow-up study of 1500 Ebola survivors in Liberia. Survivors will be evaluated every 6 months; as of October 2017, two follow-ups have been performed. Researchers will track relapses and viral persistence, characterize sequelae in various bodily systems, and do clinical studies on pharmacologic interventions and vaccines. [22]

PREVAIL III (Partnership for Research on Ebola Vaccines in Liberia III), a study of survivors and their contacts, a collaboration between NIAID and Liberia, was planned in late 2014. [23] Early results described abdominal, chest, neurologic, musculoskeletal, and ocular [24] challenges faced by survivors. [16]

PREVAIL IV examined if a medication, GS-5734, could help men with persistent Ebola virus RNA in semen to eliminate it, [25] and thereby reduce the potential risk for sexual transmission.

PREVAIL VII examined if survivors of Ebola virus disease had evidence of Ebola virus RNA in aqueous humor and outcomes of cataract surgery relative to the local population. [26]

In 2018, over two years after the resolution of the Ebola outbreak in Eastern Sierra Leone, a study was conducted of Ebola survivors, with their families used as a control group. The study was published in 2021, Looking at the results, the researchers were able to find an underlying process leading to persistent symptoms in some but not all Ebola survivors. One hypothesis suggests "ongoing inflammation due to persistent infection vs autoimmune phenomena." The authors suggest that more study is needed to come to conclusions about why some survivors continue to experience post syndrome ailments. [27]

See also

Related Research Articles

<span class="mw-page-title-main">Lassa fever</span> Viral disease spread by a type of mouse

Lassa fever, also known as Lassa hemorrhagic fever, is a type of viral hemorrhagic fever caused by the Lassa virus. Many of those infected by the virus do not develop symptoms. When symptoms occur they typically include fever, weakness, headaches, vomiting, and muscle pains. Less commonly there may be bleeding from the mouth or gastrointestinal tract. The risk of death once infected is about one percent and frequently occurs within two weeks of the onset of symptoms. Of those who survive, about a quarter have hearing loss, which improves within three months in about half of these cases.

<span class="mw-page-title-main">Ramsay Hunt syndrome type 2</span> Presentation of shingles in the geniculate ganglion

Ramsay Hunt syndrome type 2, commonly referred to simply as Ramsay Hunt syndrome (RHS) and also known as herpes zoster oticus, is inflammation of the geniculate ganglion of the facial nerve as a late consequence of varicella zoster virus (VZV). In regard to the frequency, less than 1% of varicella zoster infections involve the facial nerve and result in RHS. It is traditionally defined as a triad of ipsilateral facial paralysis, otalgia, and vesicles close to the ear and auditory canal. Due to its proximity to the vestibulocochlear nerve, the virus can spread and cause hearing loss, tinnitus, and vertigo. It is common for diagnoses to be overlooked or delayed, which can raise the likelihood of long-term consequences. It is more complicated than Bell's palsy. Therapy aims to shorten its overall length, while also providing pain relief and averting any consequences.

<span class="mw-page-title-main">Neuritis</span> Inflammation of a nerve or generally any part of the nervous system

Neuritis, from the Greek νεῦρον), is inflammation of a nerve or the general inflammation of the peripheral nervous system. Inflammation, and frequently concomitant demyelination, cause impaired transmission of neural signals and leads to aberrant nerve function. Neuritis is often conflated with neuropathy, a broad term describing any disease process which affects the peripheral nervous system. However, neuropathies may be due to either inflammatory or non-inflammatory causes, and the term encompasses any form of damage, degeneration, or dysfunction, while neuritis refers specifically to the inflammatory process.

<span class="mw-page-title-main">Zika fever</span> Infectious disease caused by the Zika virus

Zika fever, also known as Zika virus disease or simply Zika, is an infectious disease caused by the Zika virus. Most cases have no symptoms, but when present they are usually mild and can resemble dengue fever. Symptoms may include fever, red eyes, joint pain, headache, and a maculopapular rash. Symptoms generally last less than seven days. It has not caused any reported deaths during the initial infection. Mother-to-child transmission during pregnancy can cause microcephaly and other brain malformations in some babies. Infections in adults have been linked to Guillain–Barré syndrome (GBS).

Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system. Typically, both sides of the body are involved, and the initial symptoms are changes in sensation or pain often in the back along with muscle weakness, beginning in the feet and hands, often spreading to the arms and upper body. The symptoms may develop over hours to a few weeks. During the acute phase, the disorder can be life-threatening, with about 15% of people developing weakness of the breathing muscles and, therefore, requiring mechanical ventilation. Some are affected by changes in the function of the autonomic nervous system, which can lead to dangerous abnormalities in heart rate and blood pressure.

<span class="mw-page-title-main">Post-viral cerebellar ataxia</span> Medical condition

Post-viral cerebellar ataxia also known as acute cerebellitis and acute cerebellar ataxia (ACA) is a disease characterized by the sudden onset of ataxia following a viral infection. The disease affects the function or structure of the cerebellum region in the brain.

<span class="mw-page-title-main">Ebola</span> Viral hemorrhagic fever of humans and other primates caused by ebolaviruses

Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash and decreased liver and kidney function, at which point some people begin to bleed both internally and externally. It kills between 25% and 90% of those infected – about 50% on average. Death is often due to shock from fluid loss, and typically occurs between six and 16 days after the first symptoms appear. Early treatment of symptoms increases the survival rate considerably compared to late start. An Ebola vaccine was approved by the US FDA in December 2019.

<span class="mw-page-title-main">Western African Ebola epidemic</span> 2013–2016 major disease outbreak

The 2013–2016 epidemic of Ebola virus disease, centered in West Africa, was the most widespread outbreak of the disease in history. It caused major loss of life and socioeconomic disruption in the region, mainly in Guinea, Liberia and Sierra Leone. The first cases were recorded in Guinea in December 2013; the disease spread to neighbouring Liberia and Sierra Leone, with minor outbreaks occurring in Nigeria and Mali. Secondary infections of medical workers occurred in the United States and Spain. Isolated cases were recorded in Senegal, the United Kingdom and Italy. The number of cases peaked in October 2014 and then began to decline gradually, following the commitment of substantial international resources.

<span class="mw-page-title-main">ZMapp</span> Experimental treatment for Ebola virus disease

ZMapp is an experimental biopharmaceutical drug comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease. Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, a research scientist at the NML and underwent further development under license by Mapp Biopharmaceutical. ZMapp was first used on humans during the Western African Ebola virus epidemic, having only been previously tested on animals and not yet subjected to a randomized controlled trial. The National Institutes of Health (NIH) ran a clinical trial starting in January 2015 with subjects from Sierra Leone, Guinea, and Liberia aiming to enroll 200 people, but the epidemic waned and the trial closed early, leaving it too statistically underpowered to give a meaningful result about whether ZMapp worked.

<span class="mw-page-title-main">Ebola virus epidemic in Sierra Leone</span>

An Ebola virus epidemic in Sierra Leone occurred in 2014, along with the neighbouring countries of Guinea and Liberia. At the time it was discovered, it was thought that Ebola virus was not endemic to Sierra Leone or to the West African region and that the epidemic represented the first time the virus was discovered there. However, US researchers pointed to lab samples used for Lassa fever testing to suggest that Ebola had been in Sierra Leone as early as 2006.

<span class="mw-page-title-main">Ebola vaccine</span> Vaccine against Ebola

Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates against lethal infection.

<span class="mw-page-title-main">Ebola in the United Kingdom</span>

Ebola virus disease in the United Kingdom and Ireland has occurred rarely in four cases to date, namely three health workers returning from treating victims of the Ebola virus epidemic in West Africa in 2014 and 2015, and a single case in 1976, when a laboratory technician contracted the disease in a needlestick injury while handling samples from Africa. All cases recovered. As of 2023, no domestic transmission of Ebola has occurred in the United Kingdom or Ireland.

Pauline Cafferkey is a Scottish nurse and aid worker who contracted Ebola virus disease in 2014 while working in Sierra Leone as part of the medical aid effort during the West African Ebola virus epidemic. She survived the illness.

<span class="mw-page-title-main">Ebola in Nigeria</span>

Cases of the Ebola virus disease in Nigeria were reported in 2014 as a small part of the epidemic of Ebola virus disease which originated in Guinea that represented the first outbreak of the disease in a West African country. Previous outbreaks had been confined to countries in Central Africa.

<span class="mw-page-title-main">Research in management of Ebola</span>

There is a cure for the Ebola virus disease that is currently approved for market the US government has inventory in the Strategic National Stockpile. For past and current Ebola epidemics, treatment has been primarily supportive in nature.

Ian Crozier is an American physician who contracted Ebola virus disease in September 2014, while working in West Africa.

<span class="mw-page-title-main">Symptoms of COVID-19</span>

The symptoms of COVID-19 are variable depending on the type of variant contracted, ranging from mild symptoms to a potentially fatal illness. Common symptoms include coughing, fever, loss of smell (anosmia) and taste (ageusia), with less common ones including headaches, nasal congestion and runny nose, muscle pain, sore throat, diarrhea, eye irritation, and toes swelling or turning purple, and in moderate to severe cases, breathing difficulties. People with the COVID-19 infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; and a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea. In people without prior ear, nose, or throat disorders, loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of symptomatic cases.

Posner–Schlossman syndrome (PSS) also known as glaucomatocyclitic crisis (GCC) is a rare acute ocular condition with unilateral attacks of mild granulomatous anterior uveitis and elevated intraocular pressure. It is sometimes considered as a secondary inflammatory glaucoma.

Post-acute infection syndromes (PAISs) or post-infectious syndromes are medical conditions characterized by symptoms attributed to a prior infection. While it is commonly assumed that people either recover or die from infections, long-term symptoms—or sequelae—are a possible outcome as well. Examples include long COVID, Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and post-Ebola virus syndrome. Common symptoms include post-exertional malaise (PEM), severe fatigue, neurocognitive symptoms, flu-like symptoms, and pain. The pathology of most of these conditions is not understood and management is generally symptomatic.

References

  1. 1 2 Carod-Artal FJ (3 October 2015). "Post-Ebolavirus disease syndrome: what do we know?". Expert Review of Anti-Infective Therapy. 13 (10): 1185–7. doi: 10.1586/14787210.2015.1079128 . PMID   26293407.
  2. 1 2 3 4 "Clinical care for survivors of Ebola virus disease" (PDF). WHO. World Health Organization. Retrieved 5 August 2016.
  3. 1 2 Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG (April 2016). "Post-Ebola Syndrome, Sierra Leone". Emerging Infectious Diseases. 22 (4): 641–6. doi:10.3201/eid2204.151302. PMC   4806950 . PMID   26983037.
  4. ↑ Burki TK (July 2016). "Post-Ebola syndrome". The Lancet. Infectious Diseases. 16 (7): 780–781. doi: 10.1016/S1473-3099(15)00259-5 . PMID   27352759.
  5. ↑ Yasmin S. "Why Ebola Survivors Struggle with New Symptoms". Scientific American. Retrieved 2020-05-27.
  6. ↑ Neporent L (2014-09-03). "'Post-Ebola Syndrome' Persists After Virus Is Cured, Doctor Says". ABC news. Retrieved 12 May 2015.
  7. ↑ Farge E, Giahyue JH (2015-02-04). "Free from Ebola, survivors complain of new syndrome". Reuters. Dakar, Monrovia. Retrieved 12 May 2015.[ dead link ]
  8. ↑ Grady D (2015-05-07). "After Nearly Claiming His Life, Ebola Lurked in a Doctor's Eye". The New York Times. The New York Times. Retrieved 12 May 2015.
  9. ↑ Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, et al. (June 2015). "Persistence of Ebola Virus in Ocular Fluid during Convalescence". The New England Journal of Medicine. 372 (25): 2423–7. doi:10.1056/NEJMoa1500306. hdl:2328/35704. PMC   4547451 . PMID   25950269.
  10. ↑ Epstein L, Wong KK, Kallen AJ, Uyeki TM (December 2015). "Post-Ebola Signs and Symptoms in U.S. Survivors". The New England Journal of Medicine. 373 (25): 2484–6. doi: 10.1056/NEJMc1506576 . PMID   26672870.
  11. ↑ "Ebola survivors: What happens next?". Foundation for Biomedical Research. Archived from the original on 10 July 2015. Retrieved 8 July 2015.
  12. ↑ Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. (August 2015). "Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study". The Lancet. Infectious Diseases. 15 (8): 905–12. doi: 10.1016/S1473-3099(15)70152-0 . PMID   25910637.
  13. ↑ Brainard J, Pond K, Hooper L, Edmunds K, Hunter P (February 2016). "Presence and Persistence of Ebola or Marburg Virus in Patients and Survivors: A Rapid Systematic Review". PLOS Neglected Tropical Diseases. 10 (2): e0004475. doi: 10.1371/journal.pntd.0004475 . PMC   4771830 . PMID   26927697.
  14. ↑ "Preliminary study finds that Ebola virus fragments can persist in the semen of some survivors for at least nine months". WHO. World Health Organization. Archived from the original on 7 December 2016. Retrieved 5 August 2016.
  15. ↑ Fischer WA, Brown J, Wohl DA, Loftis AJ, Tozay S, Reeves E, et al. (2017). "Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After Resolution of Acute Ebola Virus Infection". Open Forum Infectious Diseases. 4 (3): ofx155. doi:10.1093/ofid/ofx155. PMC   5897835 . PMID   29670927.
  16. 1 2 Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, Moses SJ, et al. (March 2019). "A Longitudinal Study of Ebola Sequelae in Liberia". The New England Journal of Medicine. 380 (10): 924–934. doi:10.1056/NEJMoa1805435. PMC   6478393 . PMID   30855742.
  17. ↑ Kupferschmidt, Kai (12 March 2021). "New Ebola outbreak likely sparked by a person infected 5 years ago". Science. doi: 10.1126/science.abi4876 . Retrieved 19 March 2021.
  18. ↑ Steve E Bellanemail; Juliet R C Pulliam; Jonathan Dushoff; Lauren Ancel Meyers (15 October 2015). "Ebola control: effect of asymptomatic infection and acquired immunity". The Lancet. 384 (9953): 1499–1500. doi:10.1016/S0140-6736(14)61839-0. PMC   4829342 . PMID   25390569.
  19. ↑ Epstein, Lauren; Wong, Karen K; Kallen, Alexander J; Uyeki, Timothy M (17 December 2015). "Post-Ebola Signs and Symptoms in U.S. Survivors". New England Journal of Medicine. 373 (25): 2484–2486. doi: 10.1056/NEJMc1506576 . PMID   26672870.
  20. ↑ Varkey, JB; Shantha, JG; Crozier, I; Kraft, CS; Lyon, GM; Mehta, AK; Kumar, G; Smith, JR; Kainulainen, MH; Whitmer, S; Ströher, U; Uyeki, TM; Ribner, BS; Yeh, S (Jun 2015). "Persistence of Ebola Virus in Ocular Fluid during Convalescence". New England Journal of Medicine. 372 (25): 2423–2427. doi:10.1056/NEJMoa1500306. hdl:2328/35704. PMC   4547451 . PMID   25950269.
  21. ↑ Carod-Artal FJ (2015). "Post-Ebolavirus disease syndrome: what do we know?". Expert Rev Anti Infect Ther. 13 (10): 1185–7. doi: 10.1586/14787210.2015.1079128 . PMID   26293407.
  22. ↑ Jagadesh S, Sevalie S, Fatoma R, Sesay F, Sahr F, Faragher B, et al. (January 2018). "Disability Among Ebola Survivors and Their Close Contacts in Sierra Leone: A Retrospective Case-Controlled Cohort Study". Clinical Infectious Diseases. 66 (1): 131–133. doi:10.1093/cid/cix705. PMC   5833946 . PMID   29020205.
  23. ↑ Massaquoi MB, Kennedy SB, Tegli JK, Bolay FK, Kateh FN (April 2016). "Fostering collaboration on post-Ebola clinical research in Liberia". The Lancet. Global Health. 4 (4): e239. doi: 10.1016/S2214-109X(15)00323-X . PMID   27013310.
  24. ↑ Eghrari AO, Bishop RJ, Ross RD, Davis B, Larbelee J, Amegashie F, et al. (January 2021). "Characterization of Ebola Virus-Associated Eye Disease". JAMA Network Open. 4 (1): e2032216. doi: 10.1001/jamanetworkopen.2020.32216 . PMC   7786253 . PMID   33399856.
  25. ↑ "PREVAIL treatment trial for men with persistent Ebola viral RNA in semen opens in Liberia". National Institutes of Health (NIH). 2016-07-05. Retrieved 2021-01-27.
  26. ↑ Eghrari, Allen O.; Shantha, Jessica G.; Ross, Robin D.; Ryn, Collin Van; Crozier, Ian; Hayek, Brent; Gradin, Dan; Roberts, Ben; Prakalapakorn, S. Grace; Amegashie, Fred; Nishant, Kumar (2021-01-04). "Efficacy and Safety Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease: 12-Month Results From the PREVAIL VII Study". Translational Vision Science & Technology. 10 (1): 32. doi: 10.1167/tvst.10.1.32 . ISSN   2164-2591. PMC   7838547 . PMID   33520427.
  27. ↑ Bond, N. G.; Grant, D. S.; Himmelfarb, S. T.; Engel, E. J.; Al-Hasan, F.; Gbakie, M.; Kamara, F.; Kanneh, L.; Mustapha, I.; Okoli, A.; Fischer, W.; Wohl, D.; Garry, R. F.; Samuels, R.; Shaffer, J. G.; Schieffelin, J. S. (2021). "Post-Ebola Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing Cohort Study in Eastern Sierra Leone". Clinical Infectious Diseases. 73 (6): 1046–1054. doi:10.1093/cid/ciab267. PMC   8442780 . PMID   33822010.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.